Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Extract

In a commentary on justifying the value of critical care pharmacists, Dr. Erstad states that the time has come to discard the need to demonstrate the value of critical care pharmacists.1 A letter in response subsequently advised “avoiding cost avoidance” to justify critical care pharmacists’ value given the risk of overestimation of the return on investment ratio.2 This view may be through rose-colored glasses as the problem of justifying clinical pharmacists’ services across a variety of practice settings, including in critical care, remains. Indeed, a recent national survey found that only 70.8% of intensive care units (ICUs) had direct clinical pharmacist services, demonstrating a substantial need to be fulfilled nationally.3 Therefore, we wish to offer a counterargument in support of cost avoidance studies and other measures that may help generate critical care pharmacist positions in the “real world” (eg, at academic and community hospitals alike across the country), given the critical role these pharmacists have in changing the culture within their units to promote safe, effective, and cost-saving healthcare.

Issue Section:
Letters
You do not currently have access to this article.
Download all slides

Comments

0 Comments
Comments (0)
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.